Last reviewed · How we verify
NCT02995850
A Phase Ib/II Study of Efficacy and Feasibility of Cytoreductive Surgery, Extensive Peritoneal Lavage, Hyperthermicintraperitoneal Chemotherapy and Post-operative Intraperitoneal Chemotherapy Combination in Gastric Cancer With Peritoneal Metastasis
Phase 1, PHASE2 trial testing CRS+HIPEC in Gastric Cancer With Peritoneal Metastasis (PCI<12) in 25 participants. Completed in 5 May 2022.
19 April 2022
Quick facts
| Lead sponsor | Yonsei University |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 25 |
| Start date | 22 February 2017 |
| Primary completion | 19 April 2022 |
| Estimated completion | 5 May 2022 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- CRS+HIPEC — full drug profile →
Conditions studied
- Gastric Cancer With Peritoneal Metastasis (PCI<12) — all drugs for Gastric Cancer With Peritoneal Metastasis (PCI<12) →
Sponsor
Yonsei University
Who can join
19 and older, any sex, with Gastric Cancer With Peritoneal Metastasis (PCI<12). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is an open-label, non-randomized, single-center, phase Ib/II study, evaluating efficacy and feasibility of cytoreductive surgery(CRS), extensive peritoneal lavage, hyperthermic intraperitoneal chemotherapy(HIPEC) and post-operative intraperitoneal chemotherapy combination in gastric cancer with peritoneal metastasis
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT02995850
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of CRS+HIPEC
Trials testing the same drug.
- NCT05353582 — Preoperative Systemic Therapy for Colorectal Cancer Peritoneal Metastases · Phase 2 · unknown
- NCT04473339 — A Randomized Prospective Trail of HIPEC in Recurrent Ovarian Cancer Patients With HRR Mutation · Phase 3 · unknown
Other Yonsei University trials
Trials by the same sponsor.
- NCT07547592 — Gemcitabine and Docetaxel With or Without Bevacizumab (Onbevzi) for Soft Tissue Sarcoma · Phase 2 · not yet recruiting
- NCT07524101 — Moderate-Intensity Statin Plus Ezetimibe in CKD and ASCVD · NA · not yet recruiting
- NCT07506629 — Adductor Canal Block Methods in Bilateral Total Knee Arthroplasty · NA · not yet recruiting
- NCT07515716 — Effects of High Flow Humidified Oxygen on Umbilical Artery Acid-base Balance in Cesarean Section Under Spinal Anesthesia · NA · not yet recruiting
- NCT07507188 — Collaborative Clinical-translational Cohort of Amivantamab Plus Lazertinib and Amivantamab Plus Chemotherapy in Patients · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02995850 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Yonsei University
- Last refreshed: 8 August 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02995850.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing